Genomic sequencing analysis of 733 HER2-amplified Key and metastatic breast tumours unveiled important enrichment of mutations that activate RAS–MAPK signalling in Sophisticated tumours dealt with with prior anti-HER2 therapies121. These mutations, which include NF1 and HER2 activating mutations, lead to resistance to tucatinib and neratinib.What